Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 3,4 Dihydroxyphenylserine
2. 3,4 Threo Dops
3. 3,4-dihydroxyphenylserine
4. 3,4-threo-dops
5. Dl Threo 3,4 Dihydroxyphenylserine
6. Dl-threo-3,4-dihydroxyphenylserine
7. Droxidopa, (dl-tyr)-isomer
8. Erythro 3,4 Dihydroxyphenylserine
9. Erythro-3,4-dihydroxyphenylserine
10. Threo Dops
11. Threo-dops
1. 23651-95-8
2. L-dops
3. Dops
4. Northera
5. 3916-18-5
6. (2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic Acid
7. Dl-threo-droxidopa
8. Dl-threo-3,4-dihydroxyphenylserine
9. Dl-threo-dops
10. Threo-dopaserine
11. L-threodops
12. L-threo-dops
13. Dl-threo-dihydroxyphenylserine
14. Threo-dihydroxyphenylserine
15. Sm 5688
16. Chebi:31524
17. L-dihydroxyphenylserine
18. Droxidopa (l-dops)
19. Serine, 3-(3,4-dihydroxyphenyl)-, Dl-threo-
20. L-threo-dihydroxyphenylserine
21. 24a0v01wks
22. J7a92w69l7
23. Dl-threo-beta-(3,4-dihydroxyphenyl)serine
24. Droxydopa
25. L-threo-3,4-dihydroxyphenylserine
26. Norethra
27. Droxidopa [latin]
28. Threo-beta,3-dihydroxy-dl-tyrosine
29. Einecs 223-480-5
30. Beta,3-dihydroxy-dl-tyrosine Threo-
31. 3,4-dihydroxyphenylserine
32. Brn 2852792
33. Droxidopum
34. L-tyrosine, Beta,3-dihydroxy-, Threo-
35. Unii-24a0v01wks
36. Dl-threo-3-(3,4-dihydroxyphenyl)serine
37. Droxidopa [usan:inn:jan]
38. Unii-j7a92w69l7
39. (2rs,3rs)-2-amino-3-(3,4-dihydroxy-phenyl)-3-hydroxy-propionic Acid
40. L-threo 3,4-dihydroxyphenylserine
41. Northera (tn)
42. L-threo Dops
43. Dops (tn)
44. L-threo-3-(3,4-dihydroxyphenyl)serine
45. Dl-tyrosine, Beta,3-dihydroxy-, Threo-
46. Droxidopa [inn]
47. Droxidopa [jan]
48. Droxidopa [mi]
49. Threo-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid
50. Droxidopa [usan]
51. Dl-tyrosine, .beta.,3-dihydroxy-, Threo-
52. Droxidopa [vandf]
53. (-)-(2s,3r)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propionic Acid
54. Droxidopa [mart.]
55. Droxidopa [who-dd]
56. 1-14-00-00685 (beilstein Handbook Reference)
57. 1260173-94-1
58. Schembl134299
59. Gtpl7391
60. Droxidopa (jp17/usan/inn)
61. Droxidopa [orange Book]
62. Chembl2103827
63. Dtxsid6046422
64. Droxidopa (l-dops,sm-5688)
65. Dtxsid201017236
66. Bcp06516
67. Zinc1482049
68. Bdbm50103611
69. Mfcd00799030
70. S3041
71. Sm5688
72. (betar)-beta,3-dihydroxy-l-tyrosine
73. L-dops, >=98% (hplc)
74. (2s,3r)-3,4-dihydroxy-phenylserine
75. Akos015889899
76. Ccg-222060
77. Db06262
78. Sm-5688
79. Ncgc00344531-04
80. As-61328
81. Hy-13458
82. L-tyrosine, Beta,3-dihydroxy-, (betar)-
83. D4235
84. L-tyrosine, Beta,3-dihydroxy-, (beta-r)-
85. Threo-3,4-dihydroxyphenylserine, L-
86. 3,4-dihydroxyphenylserine-threo, Dl-
87. Dl-threo- Beta -(3,4-dihydroxyphenyl)serine
88. (-)-threo-3-(3,4-dihydroxyphenyl)-l-serine
89. D01277
90. D90266
91. Serine, 3-(3,4-dihydroxyphenyl)-, L-threo-
92. Ab01566868_01
93. 916a185
94. A816824
95. Q907853
96. Sr-01000883755
97. Q-201050
98. Sr-01000883755-1
99. L-tyrosine, .beta.,3-dihydroxy-, (.beta.r)-
100. D-tyrosine, .beta.,3-dihydroxy-, (.beta.s)-rel-
101. 23651-95-8,1260173-94-1(hcl)
102. (2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid
103. (2s,3r)-3-(3,4-dihydroxyphenyl)-2-amino-3-hydroxypropanoic Acid
104. (-)-(2s,3r)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propanoic Acid
105. (2rs,3rs)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxy-propanoic Acid
106. (-)-(2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic Acid
Molecular Weight | 213.19 g/mol |
---|---|
Molecular Formula | C9H11NO5 |
XLogP3 | -3.2 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 3 |
Exact Mass | 213.06372245 g/mol |
Monoisotopic Mass | 213.06372245 g/mol |
Topological Polar Surface Area | 124 Ų |
Heavy Atom Count | 15 |
Formal Charge | 0 |
Complexity | 235 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Northera |
PubMed Health | Droxidopa (Oral route) |
Drug Classes | Adrenergic, Vasopressor |
Drug Label | NORTHERA capsules contain droxidopa, which is a synthetic amino acid precursor of norepinephrine, for oral administration. Chemically, droxidopa is ()-threo-3-(3,4-Dihydroxyphenyl)-L-serine. It has the following structural formula:Droxidopa is... |
Active Ingredient | Droxidopa |
Dosage Form | Capsule |
Route | Oral |
Strength | 200mg; 300mg; 100mg |
Market Status | Prescription |
Company | Lundbeck Na |
2 of 2 | |
---|---|
Drug Name | Northera |
PubMed Health | Droxidopa (Oral route) |
Drug Classes | Adrenergic, Vasopressor |
Drug Label | NORTHERA capsules contain droxidopa, which is a synthetic amino acid precursor of norepinephrine, for oral administration. Chemically, droxidopa is ()-threo-3-(3,4-Dihydroxyphenyl)-L-serine. It has the following structural formula:Droxidopa is... |
Active Ingredient | Droxidopa |
Dosage Form | Capsule |
Route | Oral |
Strength | 200mg; 300mg; 100mg |
Market Status | Prescription |
Company | Lundbeck Na |
For treatment of neurogenic orthostatic hypotension (NOH) associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainting spells.
Droxidopa is an orally active synthetic precursor of norepinephrine that increases the deficient supply of norepinephrine in patients with NOH, thereby improving orthostatic blood pressure and alleviating associated symptoms of lightheadedness, dizziness, blurred vision, and syncope through the induction of tachycardia (increased heart rate) and hypertension.
Antiparkinson Agents
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)
C - Cardiovascular system
C01 - Cardiac therapy
C01C - Cardiac stimulants excl. cardiac glycosides
C01CA - Adrenergic and dopaminergic agents
C01CA27 - Droxidopa
Absorption
Oral bioavailability is 90%.
Route of Elimination
Droxidopa is mainly excreted in the urine, with the main metabolite being 3-O-methyldihydroxyphenylserine.
Droxidopa is metabolized by aromatic L-amino acid decarboxylase.
2-3 hours.
Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Norephinephrine acts at alpha-adrenergic receptors as a vasoconstrictor and at beta-adrenergic receptors as a heart stimulator and artery dilator.
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
84
PharmaCompass offers a list of Droxidopa API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Droxidopa manufacturer or Droxidopa supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Droxidopa manufacturer or Droxidopa supplier.
PharmaCompass also assists you with knowing the Droxidopa API Price utilized in the formulation of products. Droxidopa API Price is not always fixed or binding as the Droxidopa Price is obtained through a variety of data sources. The Droxidopa Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A DOPS manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DOPS, including repackagers and relabelers. The FDA regulates DOPS manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DOPS API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DOPS manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A DOPS supplier is an individual or a company that provides DOPS active pharmaceutical ingredient (API) or DOPS finished formulations upon request. The DOPS suppliers may include DOPS API manufacturers, exporters, distributors and traders.
click here to find a list of DOPS suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A DOPS DMF (Drug Master File) is a document detailing the whole manufacturing process of DOPS active pharmaceutical ingredient (API) in detail. Different forms of DOPS DMFs exist exist since differing nations have different regulations, such as DOPS USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A DOPS DMF submitted to regulatory agencies in the US is known as a USDMF. DOPS USDMF includes data on DOPS's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The DOPS USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of DOPS suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The DOPS Drug Master File in Japan (DOPS JDMF) empowers DOPS API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the DOPS JDMF during the approval evaluation for pharmaceutical products. At the time of DOPS JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of DOPS suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a DOPS Drug Master File in Korea (DOPS KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of DOPS. The MFDS reviews the DOPS KDMF as part of the drug registration process and uses the information provided in the DOPS KDMF to evaluate the safety and efficacy of the drug.
After submitting a DOPS KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their DOPS API can apply through the Korea Drug Master File (KDMF).
click here to find a list of DOPS suppliers with KDMF on PharmaCompass.
A DOPS written confirmation (DOPS WC) is an official document issued by a regulatory agency to a DOPS manufacturer, verifying that the manufacturing facility of a DOPS active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting DOPS APIs or DOPS finished pharmaceutical products to another nation, regulatory agencies frequently require a DOPS WC (written confirmation) as part of the regulatory process.
click here to find a list of DOPS suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing DOPS as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for DOPS API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture DOPS as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain DOPS and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a DOPS NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of DOPS suppliers with NDC on PharmaCompass.
DOPS Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DOPS GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DOPS GMP manufacturer or DOPS GMP API supplier for your needs.
A DOPS CoA (Certificate of Analysis) is a formal document that attests to DOPS's compliance with DOPS specifications and serves as a tool for batch-level quality control.
DOPS CoA mostly includes findings from lab analyses of a specific batch. For each DOPS CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DOPS may be tested according to a variety of international standards, such as European Pharmacopoeia (DOPS EP), DOPS JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DOPS USP).